Stay connected and up-to-date on the latest news and reports. It’s never been easier to know what’s going on in digital health.
%20(1).png)
In this week’s blog, guest author Ahmed Albaiti (Principal, ZS), makes a case for why the recent wave of bad news in digital health may just be the focused push that the industry needs.
Read more.png)
In the recent years, patient engagement has gained great popularity in healthcare. The most impactful and adoptable solutions come from involving patient experts, key opinion leaders and other key stakeholders in a collaborative 'co-creation' process.
Read more
Our HealthXL meetings in April covered everything from ‘Data Monetisation for MedTech Companies’ to ‘The Potential of OTC DTx Solutions’. To make sure you’re not missing out on the top insights from our communities, and get a sneak peak at some of the conversations, here are my top five takeaways.
Read more
DTx solutions have been developed, theoretically, to remove many of the barriers associated with traditional care models and be more scalable and readily available. However, these solutions are not always accessible or inclusive for the populations that could benefit from them the most.
Read more
Pharma-DTx partnerships can be a good strategy when both the pharma and the DTx companies speak the same language. While successful pilots have been demonstrated, there are challenges in scaling and sustaining innovations that generate value and return on investment (ROI) for pharma companies.
Read more
Our HealthXL meetings in March covered everything from ‘Navigating the DiGA Framework’ to ‘Leveraging Sources of US Government Funding for Digital Health’. Make sure you’re not missing out on the topics that matter the most to our communities and are plugged into the conversation.
Read more
Over the past decade, pharma’s interaction with digital health has grown more sophisticated and purposeful. In the last year however, innovation wrapped around the drug has become the object of budgetary scrutiny in pharmaceutical companies. So why continue to invest in digital health?
Read more.png)
In this blog we analyse the current landscape of RNA therapeutics and postulate on where best digital health may support this innovative area of medicine.
Read more.png)
While the healthtech sector has evolved significantly in the past few years, 2023 looks set to be another year of significant change. At our Global Gathering in Munich, startups, pharma, and investors split up into several roundtables, tackling the several topics. Here is what we learned.
Read more
Pear Therapeutics announced last week that they are looking into “strategic alternatives” that could bolster its current precarious financial situation. Pear has been on the public markets since late 2021, however, its stock price has declined over the last two years.
Read more%20(2).png)
In the recent years, patient engagement has gained great popularity in healthcare. The most impactful and adoptable solutions come from involving patient experts, key opinion leaders and other key stakeholders in a collaborative 'co-creation' process.
Read more.png)
Our HealthXL meetings in April covered everything from ‘Data Monetisation for MedTech Companies’ to ‘The Potential of OTC DTx Solutions’. To make sure you’re not missing out on the top insights from our communities, and get a sneak peak at some of the conversations, here are my top five takeaways.
Read more.png)
DTx solutions have been developed, theoretically, to remove many of the barriers associated with traditional care models and be more scalable and readily available. However, these solutions are not always accessible or inclusive for the populations that could benefit from them the most.
Read more.png)
Pharma-DTx partnerships can be a good strategy when both the pharma and the DTx companies speak the same language. While successful pilots have been demonstrated, there are challenges in scaling and sustaining innovations that generate value and return on investment (ROI) for pharma companies.
Read more.png)
Our HealthXL meetings in March covered everything from ‘Navigating the DiGA Framework’ to ‘Leveraging Sources of US Government Funding for Digital Health’. Make sure you’re not missing out on the topics that matter the most to our communities and are plugged into the conversation.
Read more.png)
Over the past decade, pharma’s interaction with digital health has grown more sophisticated and purposeful. In the last year however, innovation wrapped around the drug has become the object of budgetary scrutiny in pharmaceutical companies. So why continue to invest in digital health?
Read more.png)
In this blog we analyse the current landscape of RNA therapeutics and postulate on where best digital health may support this innovative area of medicine.
Read more
While the healthtech sector has evolved significantly in the past few years, 2023 looks set to be another year of significant change. At our Global Gathering in Munich, startups, pharma, and investors split up into several roundtables, tackling the several topics. Here is what we learned.
Read more